

ONE PACKET. ONE DOSE. ONE TIME.

Solosec[®] (secnidazole) is designed to be easy to take.^{1,2}

Solosec is the first and only antibiotic treatment for bacterial vaginosis (BV) designed to deliver a complete course of therapy in just one oral dose.^{1,3}



Simply open the packet and sprinkle the entire contents of the packet onto applesauce, yogurt, or pudding. Stir and mix.¹



Consume all of the mixture within 30 minutes.
DO NOT CHEW OR CRUNCH THE GRANULES!



You can drink a glass of water after taking Solosec to help with swallowing. Do not try to dissolve the medicine in water or any other liquid.¹



The entire contents of SOLOSEC packet should be sprinkled onto applesauce, yogurt, or pudding and consumed once within 30 minutes without chewing or crunching the granules.¹

**ONE PACKET.
ONE DOSE.
ONE TIME.**

INDICATION

SOLOSEC[®] (secnidazole) 2 g oral granules is a 5-nitroimidazole antimicrobial agent indicated for the treatment of bacterial vaginosis in adult women.

DOSAGE AND ADMINISTRATION

SOLOSEC is a single-dose therapy for oral use. The entire contents of SOLOSEC packet should be sprinkled onto applesauce, yogurt or pudding and consumed once within 30 minutes without chewing or crunching the granules. SOLOSEC is not intended to be dissolved in any liquid.

SELECT IMPORTANT SAFETY INFORMATION

- SOLOSEC is contraindicated in patients with a history of hypersensitivity to secnidazole, other ingredients of the formulation, or other nitroimidazole derivatives.

Please see Important Safety Information continued on the next page.

SELECT IMPORTANT SAFETY INFORMATION

- Vulvo-vaginal candidiasis may develop with SOLOSEC and require treatment with an antifungal agent.
- Potential risk of carcinogenicity is unknown and has not been studied. Carcinogenicity has been seen in rodents chronically treated with nitroimidazole derivatives, which are structurally related to secnidazole. Chronic use should be avoided.
- Breastfeeding is not recommended. Patients should discontinue breastfeeding for 96 hours after administration of SOLOSEC.
- Most common adverse reactions observed in clinical trials (incidence $\geq 2\%$) were vulvovaginal candidiasis, headache, nausea, dysgeusia, vomiting, diarrhea, abdominal pain, and vulvovaginal pruritus.

To report **SUSPECTED ADVERSE REACTIONS**, contact **Lupin Pharmaceuticals, Inc. at 1-844-SOLOSEC (1-844-765-6732)** or **FDA at 1-800-FDA-1088** or www.fda.gov/medwatch.

Please click here for the full [Prescribing Information](#).

References: 1. SOLOSEC [prescribing information]. Baltimore, MD: Lupin Pharmaceuticals, Inc; 2017. 2. Data on File, Physician Research. Advantage Healthcare, Inc. Prepared December 23, 2014. 3. Broumas AG, Basara LA. Potential patient preference for 3-day treatment of bacterial vaginosis: responses to new suppository form of clindamycin. *Adv Ther.* 2000;17(3):159-166.

LUPIN
PHARMACEUTICALS, INC.

© 2019 Lupin Pharmaceuticals, Inc. All rights reserved.
Solosec® is a registered trademark owned by Lupin Inc. PP-SOL-0298